The risk we bear: The effects of review speed and industry user fees on new drug safety
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Mary K. Olson, 2002. "Pharmaceutical Policy Change and the Safety of New Drugs," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 615-642.
- Peltzman, Sam, 1987.
"The Health Effects of Mandatory Prescriptions,"
Journal of Law and Economics,
University of Chicago Press, vol. 30(2), pages 207-238, October.
- Sam Peltzman, 1986. "The Health Effects of Mandatory Prescriptions," University of Chicago - George G. Stigler Center for Study of Economy and State 38, Chicago - Center for Study of Economy and State.
- Olson, Mary K., 2004. "Are novel drugs more risky for patients than less novel drugs?," Journal of Health Economics, Elsevier, vol. 23(6), pages 1135-1158, November.
- Frank R. Lichtenberg, 2005. "Pharmaceutical Knowledge-Capital Accumulation and Longevity," NBER Chapters,in: Measuring Capital in the New Economy, pages 237-274 National Bureau of Economic Research, Inc.
- Allan Begosh & John Goldsmith & Ed Hass & Randall W. Lutter & Clark Nardinelli & John A. Vernon, 2006. "Black Box Warnings and Drug Safety: Examining the Determinants and Timing of FDA Warning Labels," NBER Working Papers 12803, National Bureau of Economic Research, Inc.
- Mary K. Olson, 1997. "Firm Characteristics and the Speed of FDA Approval," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 6(1), pages 377-401, June.
CitationsCitations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
- Hostenkamp, Gisela & Lichtenberg, Frank R., 2015.
"The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence,"
Social Science & Medicine,
Elsevier, vol. 130(C), pages 162-171.
- Frank Lichtenberg & Gisela Hostenkamp, 2013. "The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence," CESifo Working Paper Series 4516, CESifo Group Munich.
- Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
- repec:spr:drugsa:v:40:y:2017:i:6:d:10.1007_s40264-017-0526-1 is not listed on IDEAS
- Collins, J. Michael & Simon, Kosali I. & Tennyson, Sharon, 2013. "Drug withdrawals and the utilization of therapeutic substitutes: The case of Vioxx," Journal of Economic Behavior & Organization, Elsevier, vol. 86(C), pages 148-168.
- Simone Ghislandi & Michael Kuhn, 2016.
"Asymmetric information in the regulation of the access to markets,"
Department of Economics Working Papers
wuwp219, Vienna University of Economics and Business, Department of Economics.
- Ghislandi, Simone & Kuhn, Michael, 2016. "Asymmetric information in the regulation of the access to markets," Department of Economics Working Paper Series 4886, WU Vienna University of Economics and Business.
- Hostenkamp, Gisela & Fischer, Katharina Elisabeth & Borch-Johnsen, Knut, 2016. "Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark," Health Policy, Elsevier, vol. 120(12), pages 1404-1411.
More about this item
StatisticsAccess and download statistics
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:jhecon:v:27:y:2008:i:2:p:175-200. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dana Niculescu). General contact details of provider: http://www.elsevier.com/locate/inca/505560 .
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.